J&J again bumps forecasts on strong immune drug sales

Tuesday’s earnings were the first since J&J officially split off its consumer drug business, now the publicly traded company Kenvue.

By Ned Pagliarulo • Oct. 17, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like AHA and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Pfizer to cut costs, lay off staff on waning demand for COVID products

Sales of Pfizer’s pill Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral drug has been delayed. Shares rose Monday on the reset guidance.

By Ned Pagliarulo • Updated Oct. 16, 2023

Pfizer wins FDA approval for its $7B colitis drug

Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.

By Jonathan Gardner • Oct. 13, 2023

Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run

Earlier this year Pfizer removed thousands of participants from a study of its Lyme disease shot over concerns the group, Care Access, wasn't meeting clinical practice standards.

By Delilah Alvarado • Oct. 12, 2023

Bayer opens California plant to make cell therapies

The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock. 

By Delilah Alvarado • Oct. 10, 2023

GSK partners with Chinese pharma to expand Shingrix sales

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

By Delilah Alvarado • Oct. 9, 2023

Apellis sales numbers show steady demand for new eye drug, despite safety worries

The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

By Kristin Jensen • Oct. 5, 2023

Moderna claims positive results in early study for combo COVID, flu shot

The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

By Delilah Alvarado • Oct. 4, 2023

Lilly names new diabetes and obesity chief as Mounjaro sales take off

Company veteran Mike Mason, who took leadership of the division four years ago, is retiring and will be replaced by immunology head Patrik Jonsson.

By Jonathan Gardner • Oct. 4, 2023

Sandoz spins out of Novartis as standalone generic drugmaker

The spinoff, now complete, is a major step in CEO Vas Narasimhan’s plan to refocus Novartis more tightly around novel prescription drugs and new technologies.

By Kristin Jensen • Oct. 4, 2023

J&J, retreating from infectious disease, partners with Sanofi on E. coli vaccine

The French vaccine giant will pay J&J $175 million to share rights to the experimental inoculation, which is currently in Phase 3 testing.

By Kristin Jensen • Oct. 3, 2023

Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.

By Ned Pagliarulo • Oct. 3, 2023

Novartis’ closely watched rare disease drug scores in kidney disorder

Called iptacopan, the experimental medicine has now scored positive results in three late-stage clinical trials, the latest in an uncommon kidney disorder known as IgA nephropathy.

By Jacob Bell • Oct. 2, 2023

Ready for open source in life sciences? Your pharma analytics journey might be

It’s time to adopt open-source technology – but not without security, compliance and guardrails.

By Mark Lambrecht, Senior Director, Health and Life Sciences Practice • Oct. 2, 2023

Novo Nordisk, Evotec partner in metabolic disease drug discovery pact

Hunting for more metabolic disease drugs, Novo plans to work with Evotec to shape early academic research into new development programs.

By Gwendolyn Wu • Sept. 26, 2023

Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

By Jonathan Gardner • Sept. 25, 2023

Eisai’s Alzheimer’s drug Leqembi approved in Japan

Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

By Ned Pagliarulo • Sept. 25, 2023

Driving innovation to benefit people living with MS

A holistic approach to R&D is key to support MS patients throughout their treatment journey.

By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023

AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

By Jonathan Gardner • Sept. 22, 2023

Alvotech gets new FDA review for Humira biosimilar

The regulator has twice rejected Alvotech’s copycat drug due to manufacturing issues with a plant in Europe.

By Jonathan Gardner • Sept. 20, 2023

PBMs, PhRMA trade blame over drug costs in House hearing

Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

By Rebecca Pifer Parduhn • Sept. 19, 2023

Novartis cancels Beigene partnership as cancer drug gains EU approval

The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

By Jonathan Gardner • Sept. 19, 2023

FTC takes aim at pharma patent tactics used to block generics

The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.

By Jonathan Gardner • Sept. 15, 2023

FDA approves updated COVID boosters from Pfizer, Moderna

Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.

By Delilah Alvarado • Sept. 11, 2023